frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 29 August 2022
DOI 10.3389/fimmu.2022.1003761

OPEN ACCESS

EDITED AND REVIEWED BY
Margaret Hibbs,
Monash University, Australia

*CORRESPONDENCE
Chang-Fu Kuo
zandis@gmail.com

SPECIALTY SECTION
This article was submitted to Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders, a section of the journal Frontiers in Immunology

RECEIVED 26 July 2022
ACCEPTED 08 August 2022
PUBLISHED 29 August 2022

CITATION
Huang Y-J, Lin C-H, Yang H-Y, Luo S-F and Kuo C-F (2022) Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis.
Front. Immunol. 13:1003761.
doi: 10.3389/fimmu.2022.1003761

Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis

Yun-Ju Huang[1,2], Chiung-Hung Lin[1,3], Huang-Yu Yang[4], Shue-Fen Luo[2] and Chang-Fu Kuo[1,2,5]*

[1]School of Medicine, Chang Gung University, Taoyuan City, Taiwan, [2]Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan, [3]Division of Thoracic medicine, Chang Gung Memorial Hospital, Taoyuan City, Taiwan, [4]Division of Nephrology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan, [5]Center for Artificial Intelligence in Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

KEYWORDS

Systemic lupus erythematosus, lupus nephritis, urine soluble CD163, urine biomarker, chronic kidney disease, macrophage, SLEDA

A Corrigendum on

Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis

by Huang Y-J, Lin C-H, Yang H-Y, Luo S-F and Kuo C-F (2022) *Front. Immunol.* 13:935700. doi: 10.3389/fimmu.2022.935700

In the published article, there was an error in Figure 2 as published. We mistakenly used the Figure 1 as Figure 2. The Figure 1 describes us CD163 in urine and SLEDA4I-2K in SLE patients while the Figure 2



FIGURE 2
Correlation between usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The renal SLE patients with high usCD163/creatinine ratios had higher SLEDAI-2K scores compared with those with low usCD163 levels. However, no difference in SLEDAI-2K score was seen between the inactive and extrarenal SLE patients. SLEDAI-2k, Systemic Lupus Erythematosus Disease Activity Index 2000.

describes usCD163/creatinine in urine and SLEDAI-2K in SLE patients. The corrected Figure 2 and its caption appear below.

In the published article, there was an error in the Funding statement. Funding from Chang Gung Memorial Hospital Research Program (CMRPG3J0031) was omitted. The correct Funding statement appears below.

Funding

This study received funding from Key Development Project of Department of Science and Technology (2015C03Bd051) and Chang Gung Memorial Hospital Research Program (CMRPG3J0031).

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note